AU2022360108A1 - Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers - Google Patents

Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers Download PDF

Info

Publication number
AU2022360108A1
AU2022360108A1 AU2022360108A AU2022360108A AU2022360108A1 AU 2022360108 A1 AU2022360108 A1 AU 2022360108A1 AU 2022360108 A AU2022360108 A AU 2022360108A AU 2022360108 A AU2022360108 A AU 2022360108A AU 2022360108 A1 AU2022360108 A1 AU 2022360108A1
Authority
AU
Australia
Prior art keywords
binding agent
binding
heavy chain
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022360108A
Other languages
English (en)
Inventor
Maria N JURE-KUNKEL
Alexander Muik
Kristina NÜRMBERGER
Nora Pencheva
Ugur Sahin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD International Business GmbH
Biontech SE
Genmab AS
Original Assignee
MSD International Business GmbH
Biontech SE
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD International Business GmbH, Biontech SE, Genmab AS filed Critical MSD International Business GmbH
Publication of AU2022360108A1 publication Critical patent/AU2022360108A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2022360108A 2021-10-06 2022-10-05 Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers Pending AU2022360108A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163253106P 2021-10-06 2021-10-06
US63/253,106 2021-10-06
US202163257901P 2021-10-20 2021-10-20
US63/257,901 2021-10-20
PCT/EP2022/077749 WO2023057535A1 (en) 2021-10-06 2022-10-05 Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers

Publications (1)

Publication Number Publication Date
AU2022360108A1 true AU2022360108A1 (en) 2024-05-02

Family

ID=84286302

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022360108A Pending AU2022360108A1 (en) 2021-10-06 2022-10-05 Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers

Country Status (10)

Country Link
US (1) US20240409653A1 (https=)
EP (1) EP4412714A1 (https=)
JP (1) JP2024538755A (https=)
KR (1) KR20240082387A (https=)
CN (1) CN119053340A (https=)
AU (1) AU2022360108A1 (https=)
CA (1) CA3233512A1 (https=)
IL (1) IL311901A (https=)
MX (1) MX2024004242A (https=)
WO (1) WO2023057535A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242827A1 (en) * 2024-05-22 2025-11-27 Genmab A/S Bispecific antibody against pd-l1 and cd137 in combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
PT3514172T (pt) 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
US20190185571A1 (en) 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN120441704A (zh) * 2019-06-26 2025-08-08 圆祥生技股份有限公司 T细胞活化抗体
EP4100059A1 (en) * 2020-02-04 2022-12-14 Genmab A/S Antibodies for use in therapy
IL304295B2 (en) * 2021-01-08 2025-07-01 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof

Also Published As

Publication number Publication date
KR20240082387A (ko) 2024-06-10
WO2023057535A1 (en) 2023-04-13
CN119053340A (zh) 2024-11-29
EP4412714A1 (en) 2024-08-14
US20240409653A1 (en) 2024-12-12
MX2024004242A (es) 2024-07-29
JP2024538755A (ja) 2024-10-23
IL311901A (en) 2024-06-01
CA3233512A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
JP6650537B2 (ja) 抗ｃｔｌａ−４抗体
KR102928003B1 (ko) Siglec-15를 위한 항체 및 이의 사용 방법
JP7809062B2 (ja) 療法において使用するための抗体
JP2019513008A (ja) Ｂｔｌａに対して特異性を有する抗体及びその使用
US20240327544A1 (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
US20250002600A1 (en) Multispecific binding agents against pd-l1 and cd137 in combination therapy
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20240409653A1 (en) Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
JP2023554422A (ja) がんの治療のための多重特異性抗体
WO2025242827A1 (en) Bispecific antibody against pd-l1 and cd137 in combination therapy
WO2024209072A1 (en) Multispecific binding agents against pd-l1 and cd137 for treating cancer
JP2026513865A (ja) がんを処置するためのｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
AU2023401158A1 (en) Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
TW202528358A (zh) 利用結合至epcam及cd137之藥劑與pd-1軸結合拮抗劑組合的治療方法
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
CN118339183A (zh) 组合中针对pd-l1和cd137的多特异性结合剂
EA052230B1 (ru) Мультиспецифические связывающие агенты против cd40 и cd137 в комбинированной терапии
EA050156B1 (ru) Антитела для применения в терапии